Data from Cryoablation Does Not Significantly Contribute to Systemic Effector Immune Responses in a Poorly Immunogenic B16F10 Melanoma Model

<div>AbstractPurpose:<p>Cryoablation is a minimally invasive procedure implemented to destroy solid tumors. It also results in the release of tumor antigens into the systemic circulation. Preclinical studies using immunogenic tumor models have shown that cryoablation evokes antitumor immune responses. The mechanisms by which cryoablation impacts immune responses in poorly immunogenic tumors have not been sufficiently explored.</p>Experimental Design:<p>We used a bilateral B16F10 melanoma model devoid of strong immunogenic antigens. Cryoablation-induced effector immune responses were investigated, also in combination with a peritumoral STING agonist and systemic anti–PD-1. Selective immune cell depletion, T-cell migration arrest, <i>in vivo</i> T-cell transplantation, and cryoablation versus surgical removal techniques were used to determine the contribution of cryoablation and immunotherapies to systemic antitumor effector immune responses.</p>Results:<p>Treatment of a tumor with cryoablation + STING agonist + anti–PD-1 resulted in the rejection of unablated, contralateral tumors. Depletion studies demonstrated that tumor rejection is essentially dependent on CD8⁺ T cells. T-cell arrest in the lymph nodes had no effect on the rejection process. Splenic CD8⁺ T cells isolated from cryoablation-treated mice with B16F10 melanoma, upon transplantation into melanoma-bearing recipients, did not impact the recipient’s tumor growth. Finally, comparison of cryoablation + STING agonist + anti–PD-1 versus surgery + STING agonist + anti–PD-1 in the bilateral tumor model showed no difference in the rejection of contralateral tumors.</p>Conclusions:<p>Cryoablation does not significantly contribute to systemic antitumor effector immune responses in a B16F10 melanoma model. Cryoablation primarily performs tumor debulking, and immunotherapy functions independently of cryoablation in eliciting antitumor effector immune responses.</p></div>